Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
NovoCure Ltd. (NVCR)
:NVCR
Holding NVCR?
Track your performance easily
Earnings Data
Report Date
Feb 27, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.34Last Year’s EPS
-0.45Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Oct 25, 2018
|% Change Since: 54.94%
|Next Earnings Date:Jul 26, 2018
Earnings Call Sentiment|Positive
The earnings call reflected significant achievements, including the approval of Optune Lua for non-small cell lung cancer and strong revenue and patient growth. However, challenges such as regulatory delays in Europe and anticipated gross margin pressures were noted. Overall, the positive highlights, particularly the FDA approval and revenue growth, outweigh the lowlights.Company Guidance
During the Novocure Q3 2024 earnings call, the company provided detailed guidance, underscoring significant metrics. Novocure reported a global active patient growth of 13% year-over-year, ending the quarter with 4,113 active patients on therapy, marking a milestone by surpassing 4,000 patients for the first time. This contributed to a 22% year-over-year increase in net revenues, amounting to $155 million. The gross margin for the third quarter improved to 77% from 75% in the prior year, driven by higher net revenue per patient and strong performance in France. Despite a net loss of $31 million, the company achieved a positive adjusted EBITDA of $2 million, reflecting a $31 million improvement from the same period last year. These financial achievements were supported by strategic initiatives aimed at prescription conversion, patient persistence, and cross-functional alignment. The call also highlighted preparations for the U.S. launch of Optune Lua for treating non-small cell lung cancer, reflecting a significant regulatory milestone with the FDA's approval of their PMA. As Novocure gears up for further market expansions in Germany and Japan, the company remains focused on its mission to extend survival in aggressive cancer types, with upcoming clinical milestones anticipated, including the Phase III PANOVA trial data later in 2024.Optune Lua Approval for Non-Small Cell Lung Cancer
FDA approved Optune Lua for treating post-platinum metastatic non-small cell lung cancer, marking a significant expansion of Novocure's therapeutic offerings.
Record Active Patient Count
Novocure's global active patient count grew by 13% year-over-year, reaching a record 4,113 patients on therapy.
22% Revenue Growth
The company reported a 22% year-over-year increase in net revenues for Q3, driven by active patient growth and improved U.S. approval rates.
Breakthrough Device Designation for Brain Metastases
The FDA granted breakthrough device designation for Tumor Treating Fields therapy for brain metastases from non-small cell lung cancer.
Positive Adjusted EBITDA
Novocure reported a positive adjusted EBITDA of $2 million, showing a $31 million improvement compared to the same period last year.
---
NVCR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
NVCR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Oct 30, 2024 | $16.89 | $16.99 | +0.59% |
| Jul 25, 2024 | $18.79 | $18.65 | -0.75% |
| May 02, 2024 | $12.74 | $14.19 | +11.38% |
| Feb 22, 2024 | $15.62 | $15.24 | -2.43% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does NovoCure Ltd. (NVCR) report earnings?
NovoCure Ltd. (NVCR) is schdueled to report earning on Feb 27, 2025, TBA Not Confirmed.
What is NovoCure Ltd. (NVCR) earnings time?
NovoCure Ltd. (NVCR) earnings time is at Feb 27, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NVCR EPS forecast?
NVCR EPS forecast for the fiscal quarter 2024 (Q4) is -0.34.
---